LENZ Sees Big Commercial Market After Presbyopia Trial Success
LENZ announced successful results from its Phase III pivotal trial of LNZ100 and plans to apply for US FDA approval in the middle of this year, with commercialization in Q2 2025.
LENZ announced successful results from its Phase III pivotal trial of LNZ100 and plans to apply for US FDA approval in the middle of this year, with commercialization in Q2 2025.